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Background: In various animal models androgens have been demonstrated to enhance follicle stimulating
hormone (FSH) activity on granulosa cells during small growing follicle stages. To assess whether similar synergism
may also exist in humans we investigated women on androgen (dehydroepiandrosterone, DHEA) supplementation
with varying concomitant FSH exposure.
Methods: In a case controlled cohort study we determine if time interval between IVF cycles of IVF treatment with
FSH had an effect on ovarian response to ovulation induction in women supplemented with DHEA. Among 85
women with known low functional ovarian reserve (LFOR), supplemented with DHEA, and undergoing at least 3
consecutive IVF cycles, 68 demonstrated short (<120 days) intervals between repeated cycles (Group 1) and were,
therefore, considered to have consistent FSH exposure. In contrast 17 women (Group 2) demonstrated long (> = 120 days)
intervals between repeated cycles and, therefore, were considered to demonstrate inconsistent FSH exposure. Trends in
oocyte yields were compared between these groups, utilizing mixed model repeated measures ANOVA, adjusted for initial
age and FSH dose.
Results: Only women in Group I demonstrated a linear increase in oocyte yields across their three cycles of
treatments (F = 7.92; df 1, 68.6; p = 0.017). Moreover, the analysis revealed a significant interaction between the
two patient groups and cycle number for retrieved oocytes (F = 6.32, df = 2, 85.9, p = 0.003).
Conclusions: This study offers preliminary confirmatory evidence that repeated short interval exposure to
androgens in combination with FSH improves human FOR. A higher level of evidence will require prospectively
randomized studies.
Keywords: Dehydroepiandrosterone (DHEA), In vitro fertilization (IVF), Diminished ovarian reserve (DOR), Oocyte
yield, Follicle stimulating hormone (FSH), Gonadotropin s, Anti-Müllerian hormone (AMH)Background
Androgens are increasingly recognized as potentially
beneficial for follicle maturation [1]. Increasing androgen
receptors appear on granulosa cells of human follicles
from transitional to primary and secondary follicle stages
[2]. Granulosa cell specific androgen receptor knockout
(ARKO) mice have provided evidence of reduced follicle* Correspondence: dbarad@thechr.com
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unless otherwise stated.progression and increased follicle atresia compared to
wild type mice at these early stages of follicle maturation
[3]. The androgen receptor at those early stages of fol-
licle development, thus, appears to play a critical role in
normal mammalian follicle development.
It has also been reported that in rodents at least one
function of androgens at these early follicle stages is in-
creasing the sensitivity of granulosa cells to follicle
stimulating hormone (FSH) [4,5]. It thus appears that
androgens and FSH at these early follicle stages acttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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experience is, however, unknown.
Investigators have recently started to integrate andro-
gen supplementation into fertility therapy. Lisi et al., for
example, used LH priming in attempts to increase an-
drogen production during folliculogenesis, reporting im-
proved embryo grades and implantation rates [6]. The
currently most widely clinically utilized androgen is de-
hydroepiandrosterone (DHEA), which has been associ-
ated with an improvement of a variety of outcomes,
especially in women with low functional ovarian reserve
(LFOR) [7].
The small growing follicle pool represents the individ-
ual’s functional ovarian reserve (FOR). Potential effects
of androgen/FSH supplementation are on the growing
follicle pool and, as a result, need to be administered for
at least six weeks [1], though benefits of DHEA have
been observed to be cumulative up to approximately
four to five months [8]. Best pregnancy results are ob-
tained if DHEA supplementation is combined with
in vitro fertilization (IVF) [7,8], and results of DHEA
supplementation directly correlate with how well DHEA
converts to testosterone [9].
Whether the above described androgen/FSH synergism
can further augment beneficial effects on small growing
follicles of androgens alone, is, however, unknown. Based
on anecdotal patient experiences, we hypothesized that
such androgen/FSH synergism can be assumed more
likely if repeated ovulation induction cycles in close prox-
imity were to produce more oocytes than repeated cycles
with more intercycle distance.
The objective of this study was, therefore, to deter-
mine whether time intervals between IVF cycles in
women on DHEA supplementation, indeed, demon-
strated such an effect.
Methods
We identified 140 women from the center’s electronic
research data bank who were supplemented with DHEA,
and underwent at least three consecutive IVF cycles. To
assess potential effect of repeated FSH exposure while
using DHEA, we subdivided these patients into those
with repeated IVF cycles within 120 days of each other
(Group 1, n = 68) and those with cycles that were spaced
at greater than 120-day intervals (Group 2, n = 72). A
120-day interval was chosen as cut off because this is
approximately the time for a small growing follicle to
move from primary to antral stage follicle [10]. Small grow-
ing follicle stages are the stage in which FSH/androgen
synergism in animal models was demonstrated [3].
Women who failed three consecutive IVF cycles in close
proximity usually demonstrated severely diminished ovarian
reserve. Women with long inter-cycle intervals, however,
were more mildly affected since some, indeed, had longintervals between IVF cycles because of an intervening
pregnancies. Women selected for Group 2, therefore, were
further matched for age and level of ovarian reserve, based
on FSH and anti-Müllerian hormone (AMH) levels, and
women with an intervening pregnancy between IVF cycles
were excluded from analysis. In all, 55 women were, there-
fore, excluded because of pregnancy or failure to meet
matching criteria for age and ovarian reserve. This left for
final analysis a comparison of 68 patients in Group 1 and
only 17 patients in Group 2.
Once diagnosed with LFOR, patients at our center re-
ceive a uniform supplementation protocol with 25 mg of
pharmaceutical grade, micronized DHEA, TID, uninter-
rupted until pregnancy (second, normally rising human
chorionic gonadotropin level) or termination of fertility
treatment attempts with autologous oocytes [7].
After at least six weeks of DHEA supplementation, a
first IVF cycle is initiated with the patient’s first menses.
All LFOR patients receive identical ovarian stimulation
in a microdose agonist protocol (leuprolide acetate,
Lupron™, Abbot Pharmaceuticals, North Chicago, IL,
USA), as previously reported [7]. Ovarian stimulation al-
ways involves a preponderance of 300 to 450 IU of FSH
(products of various manufacturers, depending on patient
preference and insurance circumstances) and 150 IU of a
human menopausal gonadotropin (hMG) product (mostly,
Repronex™, Ferring Pharmaceuticals, Parsippany-Troy
Hills, NJ, USA).
IVF cycle outcomes were assessed in every patient’s
first, second and third cycle, based on oocyte yields,
cancellation rates and number of embryos transferred.
Statistical analysis was performed using SPSS version
21.0 (IBM SPSS, Chicago IL).
Chi-square tests were used to compare proportions.
Continuous variables were presented as means ± stand-
ard deviations (SD), and tested either by Student’s t-test
and/or analysis of variance. Changes in oocyte produc-
tion across cycles were evaluated using a general linear
model for repeated measures. Linear Mixed models with
repeated measures were used to test the effects of age
and total gonadotropin dosage as covariates, with a fac-
tor identifying sets of cycles, based on </≥120 day inter-
vals between cycles. The Linear Mixed Model provides
an F statistic that allows us to make an inference about
the observed effect. Degrees of freedom (df ) were calcu-
lated using Satterthwaite approximation. All tests were
two-tailed, and a P-value of P < 0.05 was considered sta-
tistically significant.
This study involved only analyses of data derived from
our center’s anonymized research database. All of the
center’s patients sign at initial presentation an informed
consent, which allows utilization of medical records for
research purposes, as long as confidentiality of medical
records and anonymity of the patient is maintained.
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conditions the study qualified for expedited approval
from the center’s Institutional Review Board study ap-
proval # ER010813-01 Jan 13, 2013.
Pregnancy rates, quite obviously, could not be com-
pared between the two groups since patient selection
criteria in this study only allowed for pregnancies to
occur in 3rd cycles.
Results
Patient characteristics and primary infertility diagnoses
are listed in Table 1. The primary infertility diagnosis of
all women was LFOR. As the table demonstrates, mean
age, body mass index (BMI), FSH, AMH and primary in-
fertility diagnoses of both groups were similar. Mean oo-
cyte yields across all cycles were also similar between
groups, 2.87 ± 3.03 for the group 1 and 3.49 ± 3.23 for
the group 2.
Repeated measures ANOVA confirmed that in Group
1 age (p < 0.001), FSH dose (p = 0.05), oocytes retrieved
(p = 0.001) and embryos transferred (p = 0.004) signifi-
cantly increased across the three cycles, while percent-
ages of cycles with no oocytes retrieved (p = 0.024) and
canceled cycles (p = 0.006) decreased across the three
cycles of treatment for Group 1. The number of can-
celed cycles increased for Group 2 (p = 0.028) (Table 2).
Although FSH dose increased across the three cycles, in
Group 1, there was no significant interaction between
FSH dosage and cycles of treatment with respect toTable 1 Patient characteristics
Cycle interval < 120 days ≥ 120 days
N 68 17
Age (years) 40.50 ± 4.45 41.59 ± 3.16
BMI (kg/m2) 23.73 ± 3.9 23.00 ± 4.07
FSH (mIU/mL) 19.6 ± 17.9 16.7 ± 21.4
AMH (ng/mL) 0.42 ± 0.41 0.54 ± 0.40
Gonadotropin dosage/IVF cycle 6720 ± 2403 6209 ± 2646
Oocyte yield/IVF cycle 2.87 ± 3.03 3.49 ± 3.23
Race (n/%)
Caucasian 49 (72%) 10 (65%)
African 10 (15%) 3 (12%)
Asian 9 (13%) 4 (24%)
Diagnosis (n/%)
Male factor 13 (18.1%) 4 (23.5%)
Endometriosis 4 (5.6%) 1 (5.9%)
PCO 0 (0.0%) 0 (0.0%)
DOR 55 (76.4%) 11 (64.7%)
Tubal 12 (16.7%) 2 (11.8%)
Uterine 5 (6.9%) 1 (5.9%)
The two patient groups did not differ significantly in any listed characteristics.number of oocytes retrieved. This observation suggests
that the observed cycle to cycle trend for oocytes re-
trieved was not related to the small difference in FSH
dosage observed between the two groups.
A linear mixed model with repeated measures, ad-
justed for the effects of age and FSH dosage adminis-
tered during ovulation induction, was used to test for an
interaction of the effect of short vs. long cycle intervals
across three sequential cycles on trend in oocyte produc-
tion. In this model a highly significant interaction was
seen (F = 6.32, df = 2, 85.9, p = 0.003) between repeated
cycles of treatment and short vs. long cycle interval, in-
dicating a positive increase in oocyte numbers from
cycle to cycle in Group 1 but no significant increase in
Group 2.
Because of this observed interaction the change in re-
trieved oocytes across the three cycles was in subsequent
analyses evaluated separately for short and long interval
treatment groups.
Repeated measures ANOVA, adjusted for age and FSH
dose, revealed a linear increase in oocyte yields for women
with short inter-cycle intervals < 120 days (Group 1)
across the three cycles of treatments (F = 7.92; df 1, 68.6;
p = 0.017), while women with cycle interval of ≥ 120 days
(Group 2) did not demonstrate such an effect.
To better understand the possible effects of gonado-
tropin dosage and of levels of ovarian reserve, we per-
formed further analyses of Group 1: Oocyte yields in
Group 1 increased from cycle to cycle independently of
gonadotropin dosage administered for ovulation induc-
tion (Figure 1). Subdividing Group 1 patients further
into poor and good prognosis patients, based on an
AMH cut off of 1.05 ng/mL, representing, independent
of age, the cut-off AMH value that discriminates be-
tween better and poorer IVF pregnancy chances [11],
the increase in oocyte yields was similar in both sub-
groups (Figure 2).
The definition of both study groups did not allow for
assessment of pregnancies in 1st and 2nd IVF cycles
since, by patient selection criteria, they had to be zero.
There were 4 clinical pregnancies in Group 1 patients
(5.9%) in their third treatment cycle. In contrast, Group 2
patients experienced no pregnancies in third cycles (n.s.).
Discussion
While there has been an ongoing concern that repeated
cycles of ovulation induction might deplete ovarian re-
serve [12-14], existing evidence suggests that in most
cases ovarian yields in IVF are constant across repeated
cycles [15]. This study offers evidence that among
women with severe LFOR, using androgen supplementa-
tion with DHEA, oocyte yields increase across repeated
cycles when the interval between cycles is 120 days or
less (Table 2). This suggests a potential functional
Table 2 Oocyte yields in 1st - 3rd cycles among patients who completed three cycles of treatment with < or ≥120 days
interval between cycles
N Cycles of treatment P (linear trend)
1st cycle 2nd cycle 3rd cycle
Group 1 - Time < 120 days
Age (years) 68 40.2 ± 4.4 40.4 ± 4.3 40.5 ± 4.3 0.001
FSH Dose (units) 68 6519 ± 2202 6486 ± 2344 7381 ± 2355 0.05
No Oocytes 68 23 (33.8)a 17 (25.0) 11 (16.2)a 0.024
Oocyte (total) 68 2.81 (2.02 - 3.60)b,c 3.84 (2.88 - 4.80)b 4.50 (3.48 - 5.53)c 0.001
Embryos transferred 68 1.10 (0.78-1.42)b 1.37 (0.99-1.74) 1.59 (1.2-1.95)b 0.004
Cancelled Cycles 68 32.4% (23–42)d 18% (8–27) 13% (4–23)d 0.006
Group 2 - Time ≥ 120 days
Age (years) 17 41.6 ± 3.2 42.2 ± 3.0 42.5 ± 3.2 0.001
FSH Dose (units) 17 6965 ± 2712 6520 ± 2288 5070 ± 2714 0.08
No Oocytes 17 2 (11.8) 4 (23.5) 5 (29.4) 0.22
Oocyte (total) 17 4.35 (2.78 – 5.92) 3.35 (1.78 - 4.93) 2.77 (1.19 – 4.33) 0.185
Embryos transferred 17 1.24 (0.62-1.85) 1.06 (0.44-1.67) 0.82 (0.21-1.44) 0.60
Cancelled Cycles 17 0 0 18% (7–29) 0.028
Values are presented as means (95% confidence intervals) or ± standard deviation.
ap = 0.03; bp = 0.003; cp = 0.001; dp = 0.018.
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supplementation in women with LFOR.
Clinically, the observed increased oocyte yield suggests
that patients with LFOR who fail to achieve pregnancy in
one cycle may benefit from closely scheduled consecutive
IVF cycles, taking advantage of a possible DHEA/FSHFSH dose (total units per cycle)
























Figure 1 Total gonadotropin -dosages used in 3 cycles in
Group 1. The figure demonstrates increases in oocyte yields from
1st to 3rd IVF cycle in Group 1 patients independent of gonadotropin
dosage administered.synergism. Such an approach is contradictory to current
practice patterns, which favor breaks between cycles re-
serve [12-14].
Animal data strongly suggest synergistic effects of an-
drogens and FSH at small growing follicle stages [3].

























Figure 2 Oocyte numbers retrieved in Group 1. Patients in
3 cycles depending on AMH level cut off 1.05 ng/mL. This figure
demonstrates increases in oocyte yields between 1st and 3rd cycle
independent of the woman’s AMH levels.
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that would allow us to make inferences about androgen/
FSH interaction at early stages of follicle maturation. We
hypothesized that consecutive IVF cycles, if close enough
together, should offer relatively steady FSH exposure.
This idea arose from observations of our center’s DHEA
index patient, who had undergone nine consecutive IVF
cycles, month after month, demonstrating evidence of
steadily improving FOR, despite significantly advancing
age during cycle progression [16].
Previous studies found an association of numbers of
small growing follicles (i.e., FOR) with IVF outcomes
[17-19]. As Table 2 demonstrates, closely spaced ovula-
tion induction cycles with repeated FSH exposure in
parallel to DHEA supplementation significantly in-
creased oocyte yields from cycle to cycle, while ab-
sence of steady FSH exposure results in no significant
change in oocyte numbers. Moreover, the positive ef-
fects observed in Group 1 were similar at all severity
levels of LFOR, whether defined by gonadotropin stimula-
tion dosage (Figure 1) or AMH levels (Figure 2), support-
ing the idea that this increase represents synergism
between androgens and gonadotropin s.
A diagnosis of LFOR was in this study reached based
on age-specific ovarian reserve (OR) criteri [20,21].
Highly abnormal FSH levels of 19.6 ± 17.9 and 16.7 ±
21.4 mIU/mL and AMH levels of 0.42 ± 41 ng/mL and
0.54 ± 0.40 (Table 1), respectively, clearly indicate how
adversely patients in this population were affected.
The observed decline in oocyte number in Group 2
was only nominal. It, nevertheless, was surprising since
we expected to find no change in oocyte numbers in this
group over three consecutive cycles. The data in this
group, however, demonstrate an increase in cycle cancel-
lations in third cycles. Since canceled cycles statistically
were treated as “0” oocytes, this observation may par-
tially explain the nominal decline. Furthermore, longer
cycle intervals, of course, also lead to proportionally
greater reproductive aging, although each of these ana-
lyses was also adjusted for age.
We previously reported that an AMH value of
1.05 ng/mL discriminates at all ages between better
and poorer IVF pregnancy chances in women with
LFOR [11]. While there remains some debate among
experts concerning the best AMH cut-off for predic-
tion of pregnancy [11,22-25], patients with higher
AMH will respond more effectively to ovulation induc-
tion than those with lower AMH levels [22,26-28].
Therefore, we further subdivided our already initially
adversely selected patients into women with more se-
vere DOR (AMH ≤ 1.05 ng/mL) and those with milder
DOR and better IVF prognosis (AMH >1.05 ng/mL).
As Figure 2 demonstrates, both categories of AMH
performed quite similarly across the three cycles oftreatment among Group 1 patients, suggesting that an-
drogen/FSH synergism is effective at all severity levels
of LFOR.
Strengths and limitations
Strength of this analysis is that the population studied is
comprised of an unusually large number of women with
LFOR, undergoing repeated cycles of IVF. Furthermore,
study participants in both groups were very carefully
matched.
As noted in Table 2 we did observe a nominal increase
in gonadotropin dosage across the three cycles of treat-
ment in Group 1, and a nominal decrease in gonadotropin
dosage in Group 2. We adjusted for cycle gonadotropin
dosage in all of our models. It, however, is possible that
such adjustments may not fully correct for an effect of dif-
ferences in gonadotropin dosage. Though quite unlikely,
we, therefore, cannot completely rule out that observed
differences in ovarian response, at least in part, could be
due to these differences in gonadotropin doses.
Epsteiner et al. [29] reported increased oocyte yields
across repeated cycles among women with normal ovar-
ian reserve, however the cycle interval in that study was
allowed to vary up to one year. That study found that in-
crease in gonadotropin dosage was not associated with
an increase in oocyte yield among women with dimin-
ished ovarian reserve.
While it is also possible that the observed change in
oocyte yield over the course of three observations repre-
sents regression to the mean, the clear difference in
trend of oocytes retrieved across cycles was observed
using a repeated measures analysis that examined the
change in oocyte production across cycles of treatment.
This statistical analysis was not dependent on absolute
difference in oocytes retrieved per cycle between each
group. Furthermore, for Group 1 an increase in oocytes
from cycle to cycle was seen at all levels of gonadotropin
use, and among both, severe and less severe cases of
LFOR. In contrast, there was no evidence of increased
oocyte production among patients in Group 2.
The principal weakness of this analysis is that it is based
on retrospective data. To obtain a higher level of evidence
for synergism between androgens and gonadotropin s in a
clinical setting would require a prospective randomized
controlled trial with DHEA/placebo, fixed gonadotropin
dosages and fixed long and short inter-cycle intervals.
Given the retrospective design and small numbers of
patients it is not possible to draw conclusion about the
effect of treatments on pregnancy chances. It, neverthe-
less is remarkable that in Group 1, even in 3rd cycles,
pregnancies were still established, once more confirming
that with appropriate treatment, pregnancies can still be
established in women frequently believed by many to be
beyond help with utilization of autologous oocytes.
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While other authors have reported no change in oocyte
yields in consecutive IVF cycles, except for decreases at-
tributed to advancing female age [30-32], this study
demonstrates that oocyte yields under androgen/FSH
supplementation continue to increase through three
closely-spaced consecutive IVF cycles. This observation
suggests that women with severe LFOR, who despite
limited pregnancy chances, wish to pursue IVF with au-
tologous oocytes, should, at least, consider three con-
secutive cycles. Whether here observed rise in oocyte
yield continues with additional time of supplementation
exposure to androgen/FSH is not known.
This study further suggests the possibility of new ovar-
ian stimulation protocols specifically directed at early
stages of follicle maturation. Such a protocol could use
low dose gonadotropin preparations along DHEA sup-
plementation for two to three months to increase testos-
terone levels, advancing small follicle cohorts into
gonadotropin -sensitive stages of follicle maturation, at
which point a routine stimulation could be initiated.
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